Coherus BioSciences, Inc.(CHRS)

Description: Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

---

Keywords: Medicine Biotechnology Biopharmaceutical Immunology Breast Cancer Chemotherapy Rheumatoid Arthritis Psoriasis Treatment Of Breast Cancer Biosimilar Immunosuppressants Recombinant Proteins Neutropenia Tnf Inhibitors Adalimumab Biosimilar Products Etanercept Pegfilgrastim

---

Home Page: www.coherus.com

CHRS Technical Analysis

333 Twin Dolphin Drive
Redwood City, CA 94065
United States
Phone: 650 649 3530

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)